• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd.

    11/14/24 7:23:29 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care
    Get the next $QNRX alert in real time by email
    SC 13G/A 1 sch13g.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No. 2)*
     

     
    Quoin Pharmaceuticals Ltd.
     
     
    (Name of Issuer)
     

     
    American Depositary Shares
     
     
    (Title of Class of Securities)
     

     
    74907L300
     
     
    (CUSIP Number)
     

     
    September 30, 2024
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Lind Global Fund II LP
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
    62,500
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    62,500
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    62,500(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    1.2%
     
    12
    Type of Reporting Person (See Instructions)
    PN
     
    (1) The reporting person’s ownership consists of 62,500 warrants to purchase shares of common stock (the “Warrants”).


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Lind Global Partners II LLC
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    62,500
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    62,500
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    62,500(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    1.2%
     
    12
    Type of Reporting Person (See Instructions)
    OO
     
    (1) The reporting person’s ownership consists of 62,500 Warrants.

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Jeff Easton
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    62,500
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    62,500
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    62,500(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    1.2%
     
    12
    Type of Reporting Person (See Instructions)
     
    IN
     

    (1) The reporting person’s ownership consists of 62,500 Warrants.


    Item 1.
    (a)
    Name of Issuer
     
     
    Quoin Pharmaceuticals Ltd.
    (b)
    Address of Issuer’s Principal Executive Offices
     
    42127 Pleasant Forest Court
    Ashburn, VA 20148

    Item 2.
    (a)
    Name of Person Filing
     
     
    This statement is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):
     
    •    Lind Global Fund II LP, a Delaware limited partnership;
    •    Lind Global Partners II LLC, a Delaware limited liability company; and
    •    Jeff Easton, an individual and a citizen of the United States of America.
     
    Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    Jeff Easton, the managing member of Lind Global Partners II LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    The address of the principal business office for each of the Reporting Persons is:
     
    444 Madison Ave, Floor 41
    New York, NY 10022
     
    (c)
    Citizenship
     
     
    See Row 4 of cover page for each Reporting Person.
     
    (d)
    Title of Class of Securities
     
     
    American Depositary Shares
     
    (e)
    CUSIP Number
     
     
    74907L300

    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    Not applicable.
    Item 4.
    Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a)
    Amount Beneficially Owned
     
     
     See Row 9 of cover page for each Reporting Person.
     
    (b)
    Percent of Class
     
     
    See Row 11 of cover page for each Reporting Person.
     

    (c)
    Number of shares as to which such person has:
     
     
    (i)
    sole power to vote or to direct the vote
       

    See Row 5 of cover page for each Reporting Person.
     
     
    (ii)
    shared power to vote or to direct the vote
       
     
    See Row 6 of cover page for each Reporting Person.
     
     
    (iii)
    sole power to dispose or to direct the disposition of
       

    See Row 7 of cover page for each Reporting Person.
     
     
    (iv)
    shared power to dispose or to direct the disposition of
       
     
    See Row 8 of cover page for each Reporting Person.
     

    Item 5.  Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.
    Item 6.  Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group
    Not applicable.
    Item 9.
    Notice of Dissolution of Group
    Not Applicable.
    Item 10.
    Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Exhibits
    Exhibit
    99.1            Joint Filing Application by and among the Reporting Persons

    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    November 14, 2024
    LIND GLOBAL FUND II LP
       
    By:
     
    Lind Global Partners II LLC
     
     
    its General Partner
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    LIND GLOBAL PARTNERS II LLC
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    JEFF EASTON
     
    By:
     
    /s/ Jeff Easton

    Get the next $QNRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QNRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QNRX
    SEC Filings

    View All

    Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Material Modification to Rights of Security Holders, Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)

    8/21/25 5:28:33 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Quoin Pharmaceuticals Ltd.

    10-Q - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)

    8/7/25 4:58:47 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)

    8/7/25 4:57:58 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $QNRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by Chief Operating Officer Carter Denise P.

    4/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    6/13/25 8:09:43 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form 4 filed by Chief Executive Officer Myers Michael

    4/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    6/13/25 8:06:37 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Culverwell Anthony James

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    6/3/25 4:00:21 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $QNRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Carter Denise P. bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,180% to 602,648 units (SEC Form 4)

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    12/27/24 5:17:23 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Myers Michael bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,176% to 602,808 units (SEC Form 4)

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    12/27/24 5:16:51 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Director Culverwell Anthony James bought $45,000 worth of Ordinary Shares (100,000 units at $0.45), increasing direct ownership by 31,546% to 100,317 units (SEC Form 4)

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    12/27/24 5:15:10 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $QNRX
    Leadership Updates

    Live Leadership Updates

    View All

    Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy

    ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appointment of its new Chief Financial Officer as the Company advances its lead product candidate, QRX003, through pivotal clinical studies and prepares for potential commercialization. Quoin has appointed Sally Lawlor, BCL, FCA, as its new Chief Financial Officer, effective immediately. Ms. Lawlor is an accomplished finance executive with over 20 years of experience in financial leadership roles in public and private companies as well as a Big Four accounting fir

    8/18/25 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $QNRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quoin Pharmaceuticals' NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton Syndrome

    ASHBURN, Va., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that its NETHERTON NOW awareness campaign has surpassed a major milestone, achieving more than one million video views and over 14 million impressions. Launched to give patients, families, and experts a greater voice, NETHERTON NOW has become a global platform shining a spotlight on the painful realities of Netherton Syndrome (NS), a rare and devastating genetic skin disease. The campaign's videos, which highlight personal stories and clinical perspectives, have been widel

    8/21/25 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy

    ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appointment of its new Chief Financial Officer as the Company advances its lead product candidate, QRX003, through pivotal clinical studies and prepares for potential commercialization. Quoin has appointed Sally Lawlor, BCL, FCA, as its new Chief Financial Officer, effective immediately. Ms. Lawlor is an accomplished finance executive with over 20 years of experience in financial leadership roles in public and private companies as well as a Big Four accounting fir

    8/18/25 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton

    ASHBURN, Va., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the release of the fourth episode in its NETHERTON NOW video series. This installment features Mandy Aldwin-Easton, a Netherton Syndrome patient, and a widely recognized, passionate advocate for people living with rare diseases. Mandy serves as Medical and Communications Manager and Co-founder of the UK-based Ichthyosis Support Group and is President of the European Network for Ichthyosis. In the video, Mandy shares her personal journey living with Netherton Syndrom

    8/12/25 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $QNRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd.

    SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    11/14/24 7:23:29 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd. (Amendment)

    SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    2/13/24 8:11:42 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd. (Amendment)

    SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    2/14/23 2:40:46 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $QNRX
    Financials

    Live finance-specific insights

    View All

    Quoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate Update

    -  Positive 6 Month Clinical Data Reported for Ongoing Pediatric Netherton Syndrome Study -  FDA Clears Second Pivotal Study of QRX003 for Netherton Syndrome -  Initial Positive Data Announced from Peeling Skin Syndrome Pediatric Study -  Orphan Drug Designation Granted by European Medicines Agency for QRX003 -  Rare Pediatric Disease Designation Awarded by U.S. FDA -  NETHERTON NOW Campaign Expanded with New Patient and Expert Video Releases ASHBURN, Va., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases provided a corporate upda

    8/7/25 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results

    Continued Progress in Ongoing Late-Stage Netherton Syndrome Studies Announced Positive Clinical Data for Adult and Pediatric Netherton Patients Provided Clear Visual Evidence of QRX003 Mechanism of Action Patent Portfolio Expanded to Support Pipeline GrowthLaunch of NETHERTON NOW Advocacy Initiative ASHBURN, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the quarter ended March 31, 2025. Quoin CEO Dr. Michael Myers

    5/13/25 8:00:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results

    Quoin Initiates Peeling Skin Syndrome Clinical Program Further Expansion of International Reach for Netherton Syndrome Clinical Trials Significant Insider Share Purchases by the Entire Management Team ASHBURN, Va., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical-stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the three and nine months ended Sept. 30, 2024. Quoin CEO Dr. Michael Myers said, "The third quarter has been marked by notable achievements, including expanding the c

    11/7/24 8:00:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care